



Polymer Factory Receives Approx. SEK 2.05 Million Through 100% Exercise of Warrants of Series TO1

Polymer Factory Sweden AB ("Polymer Factory" or the "Company") today announces that all 2,737,772 outstanding warrants of series TO1 have been exercised by investors. Through the exercise, the Company will receive approximately SEK 2,053,329 before deduction of transaction costs.

"It is encouraging and demonstrates strength that 100 percent of all warrants have been exercised," says Mats Wallner, CEO of Polymer Factory. "This shows continued strong confidence from our investors and provides us with increased resources to execute on our growth plans."

The subscription period for the TO1 warrants ended on 12 of september 2025. Each warrant entitled the holder to subscribe for one (1) new share in the Company. As a result, the number of shares in Polymer Factory will increase by 2,737,772, thereby strengthening the Company's capital base for future initiatives.

This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-09-2025 08:00 CET.

For more information, please contact:

Mats Wallner, Acting CEO

Phone: +46 (0) 70 951 95 06

E-mail: mats.wallner@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company's dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company's vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company's dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.